Century Therapeutics, INC Form 4 insider transactions

Chief Technology and Manufacturing Officer Gregory Russotti sold 2,584 shares of Century Therapeutics to cover tax obligations.

SVP of Finance & Operations Douglas Carr sold 1,654 shares of Century Therapeutics to cover tax withholding obligations.

CEO Brent Pfeiffenberger disposed of 13,849 shares of Century Therapeutics to satisfy tax obligations related to RSU vesting.

Chief Scientific Officer Chad Cowan reported the withholding of 358 shares to satisfy tax obligations upon RSU vesting.

Director Alessandro Riva was granted 74,000 stock options in Century Therapeutics, Inc. (IPSC) on June 11, 2026.

Director Daphne Quimi was granted 74,000 stock options in Century Therapeutics, Inc. as part of an equity incentive.

Director Martin Patrick Murphy was granted 74,000 stock options in Century Therapeutics, Inc. as part of standard equity compensation.

Director Han Myung Lee was granted 74,000 stock options in Century Therapeutics, Inc. as part of standard compensation.

Century Therapeutics director Kimberly Blackwell was granted 74,000 stock options with an exercise price of $2.24, vesting in 2027.

Century Therapeutics reports a Form 4 filing detailing the sale of shares by Chief Technology and Manufacturing Officer Gregory Russotti to cover tax withholding obligations.

Century Therapeutics SVP Finance & Operations Douglas Carr sold company shares to cover tax withholding obligations upon vesting of restricted stock units.

Century Therapeutics President and CEO Brent Pfeiffenberger reported a transaction involving the withholding of shares to cover tax obligations.

Century Therapeutics President and CEO Brent Pfeiffenberger reported a transaction involving common stock on May 15, 2026.

SVP of Finance & Operations Douglas Carr sold 264 shares of Century Therapeutics to cover tax withholding obligations related to RSU vesting.

Century Therapeutics, Inc. reports the grant of stock options to Director Martin Patrick Murphy.

Chad Cowan, Chief Scientific Officer at Century Therapeutics, reported a transaction involving the sale of common stock.

Century Therapeutics' SVP of Finance & Operations, Douglas Carr, sold 7,043 shares of common stock to cover tax withholding obligations.

Century Therapeutics Officer Gregory Russotti sold 10,076 shares of common stock to cover tax withholding obligations related to RSU vesting.

Century Therapeutics CEO Brent Pfeiffenberger disposed of 55,397 common shares to cover tax liabilities related to restricted stock unit vesting.

Century Therapeutics' Chief Scientific Officer, Chad Cowan, reported a disposition of 1,431 common shares to cover tax obligations related to restricted stock unit vesting.

Century Therapeutics' SVP of Finance & Operations, Douglas Carr, sold 323 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Century Therapeutics' President and CEO, Brent Pfeiffenberger, was granted 475,000 Restricted Stock Units and 945,000 stock options, aligning his incentives with long-term shareholder value.

Century Therapeutics' Chief Technology and Manufacturing Officer, Gregory Russotti, received significant equity awards, including 135,000 restricted stock units and options for 265,000 shares.

Century Therapeutics' Chief Scientific Officer, Chad Cowan, received significant equity grants including restricted stock units and stock options.

Century Therapeutics' SVP of Finance & Operations, Douglas Carr, received 110,000 restricted stock units and options for 225,000 shares.

Century Therapeutics' Chief Scientific Officer, Chad Cowan, disposed of 1,611 common shares to cover tax withholding obligations related to restricted stock unit vesting.

Century Therapeutics' Chief Scientific Officer, Chad Cowan, acquired 58,060 shares of common stock at $0.8483 per share.

Century Therapeutics' President and CEO, Brent Pfeiffenberger, acquired 52,000 shares of common stock at a weighted average price of $0.5837.

Century Therapeutics' President and CEO, Brent Pfeiffenberger, disposed of 463 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Century Therapeutics, Inc. granted Director Lee Han Myung 88,000 stock options with a $0.592 exercise price, vesting over 36 months.